Sydney Boyle

Sydney Boyle.jpg

Sydney Boyle

$0.00

2017-18 Contributor

Sydney graduated with a JD from the University of Denver Sturm College of Law in December 2018. Previously, she graduated magna cum laude from, Colorado State University with a Bachelor's in Business Administration with a concentration in Marketing, a certificate in International Business, and a minor in Political Science. Prior to attending law school she worked in Business and Strategic Planning at Hewlett Packard and worked in the Legal and Regulatory Department at Time Warner Telecom.

In addition to contributing to The Race to the Bottom, Sydney is involved with DU Moot Court competitions. Her legal interests include corporate litigation and compliance, and she is pursuing a certificate in the Corporate and Commercial Law.

Outside of law school, she enjoys camping and hiking with her puppy Ari, cooking, and as a Colorado native she looks forward to rooting for the Broncos and Avalanche on game day.

Connect with Sydney on LinkedIn.

Add To Cart
Student and Faculty Blog of University of Denver Sturm College of Law
Regulatory Landscape of Cryptocurrency

With the popularity and growth of cryptocurrencies many companies are using initial coin offerings (“ICOs”) to raise capital. ICOs allow investors to exchange typical currency for a coin or token. The ICO market continues to grow—in 2017 an estimated $4 billion was raised through ICOs. (Jay Clayton, U.S. Securities and Exchange Commission). So far, 2018 has seen $2 billion raised through ICOs. (David Sacks and Josh Stein, Harbor). Funding a venture through a cryptocurrency gives companies and individuals the ability to make transfers regardless of geographic location, and it has lower transaction costs than traditional financing methods. Using cryptocurrencies, however, also has drawbacks—mainly anonymity of purchasers and sellers coupled with a lack of government regulation.

No-Action Letter for Pfizer Inc. Permitted Exclusion of Shareholder Proposal Seeking Report on the Risks from Raising Drug Prices

In Pfizer Inc. 2018 BL 030118 (March 1, 2018), Pfizer Inc. ("Pfizer") asked the staff of the Securities and Exchange Commission (“SEC”) to permit the omission of a shareholder proposal submitted by Trinity Health (“Proponents”) requesting Pfizer disclose the risks from rising pressure to contain U.S. prescription drug prices and explain how Pfizer plans to mitigate those risks. The SEC issued the requested no action letter allowing for the exclusion of the proposal under Rule 14a-8(i)(10).

Charles McDonald v. John P. Abizaid et. Al.: Stay Granted During Pendency of SEC Action
In re SandRidge Energy, Inc., Shareholder Derivative Litigation: Denial of Attorneys' Fees and Appeal Dismissed as Moot
No-Action Letter for ExxonMobil Denied Exclusion of Proposal Concerning Increasing Shareholder Distributions to Prevent Losses from Climate Change Related Risks of Stranded Carbon Assets
Second Circuit Affirms Dismissal of Shareholder’s Claims against Corporate Insider Seeking Disgorgement of "Short-Swing" Profits
U.S. v. Klein: Ex-Law Firm Partner Convicted of Insider Trading